Axonics Modulation Technologies/AXNX

$68.63

0.35%
-
1D1W1MYTD1YMAX

About Axonics Modulation Technologies

Axonics, Inc. is a medical technology company, which develops and commercializes products to treat bladder and bowel dysfunction. It has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10 cubic centimeters (cc) in volume, utilizes constant current stimulation, a recharge-free patient remote control and offers broad magnetic resonance imaging (MRI) access. Its SNM systems include an easy-to-use wireless patient remote control that does not require recharging or replacement batteries. It also offers a clinician programmer that guides the implanting physician through lead placement and stimulation programming.

Ticker

AXNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Raymond Cohen

Employees

610

Headquarters

Irvine, United States

AXNX Metrics

BasicAdvanced
$3.47B
Market cap
-
P/E ratio
-$0.25
EPS
0.57
Beta
-
Dividend rate

What the Analysts think about AXNX

Analyst Ratings

Majority rating from 15 analysts.
Hold

Price Targets

Average projection from 11 analysts.
4.52% upside
High $75.00
Low $71.00
$68.63
Current price
$71.73
Average price target

AXNX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
4.18% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$93.1M
0.32%
Net income
$3.9M
-153.42%
Profit margin
4.18%
-153.18%

AXNX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 245.45%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.01
-$0.19
-$0.15
$0.08
-
Expected
-$0.24
-$0.29
-$0.11
-$0.06
$0.06
Surprise
-104.14%
-33.87%
32%
-245.45%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Axonics Modulation Technologies stock

Buy or sell Axonics Modulation Technologies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing